Neurobiology of cognitive impairment in Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 12, Issue 12, 2012, Pages 1451-1466

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

biomarkers; clinical features; consensus guidelines; dementia with Lewy bodies; diagnostic criteria; mild cognitive impairment; neuroimaging; neuropathology; Parkinson's disease dementia; treatment options

Indexed keywords

ACETYLCHOLINESTERASE; ALPHA SYNUCLEIN; AMYLOID; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; LEUCINE RICH REPEAT KINASE 2; MEMANTINE; PLACEBO; PRAMIPEXOLE; RIVASTIGMINE; TAU PROTEIN; TRICYCLIC ANTIDEPRESSANT AGENT;

AGE; ALZHEIMER DISEASE; AMNESIA; APHASIA; ATTENTION DISTURBANCE; BRADYKINESIA; BRAIN CELL; BRAIN CORTEX ATROPHY; BRAIN METABOLISM; CEREBROSPINAL FLUID; CHOLINERGIC SYSTEM; CLINICAL FEATURE; COGNITIVE DEFECT; COGNITIVE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINERGIC SYSTEM; DSM-IV; EXECUTIVE FUNCTION; FLUENCY DISORDER; GENE MUTATION; GENETIC ASSOCIATION; GRAY MATTER; HUMAN; INCIDENCE; LANGUAGE DISABILITY; LEWY BODY; MEMORY DISORDER; MEYNERT BASAL NUCLEUS; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MORPHOMETRICS; MORTALITY; MULTICENTER STUDY (TOPIC); NERVE CELL NETWORK; NEUROBIOLOGY; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHIATRY; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREVALENCE; PROTEIN CEREBROSPINAL FLUID LEVEL; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SYSTEMATIC REVIEW (TOPIC); TRANSCRANIAL MAGNETIC STIMULATION; VISUAL HALLUCINATION; VOXEL BASED MORPHOMETRY; WHITE MATTER; WHITE MATTER INJURY;

COGNITION DISORDERS; HUMANS; PARKINSON DISEASE;

EID: 84871089477     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.131     Document Type: Review

References (221)

1. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov. Disord. 27(1), 8-30 (2012).
2. Jellinger KA. Synucleinopathies. In: Encyclopedia of Movement Disorders, Volume 3. Kompoliti K, Verhagen-Metman L (Eds). Academic Press, Oxford, UK, 203-207 (2010).
3. Non-Motor Symptoms of Parkinson's Disease. Chaudhuri KR, Tolosa E, Schapira A, Poewe W (Eds). Oxford University Press, Oxford, UK (2009).
4. Tolosa E, Santamaria J, Gaig C, Compta Y. Nonmotor aspects of Parkinson's disease. In: Movement Disorders 4. Schapira AHV, Lang AET, Fahn S (Eds). Saunders-Elsevier, Philadelphia, PA, USA, 229-251 (2010).
5. Charcot J-M. De la paralysie agitante. Oeuvres Complétes: Leçons sur les maladies du systéme nerveux. Vol 1. Paris: Bureaux du Progrés Mèdical, 1872;
6. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 11(8), 697-707 (2012).
7. Meireles J, Massano J. Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. Front. Neurol. 3, 1-15 (2012).
8. Barone P, Aarsland D, Burn D, Emre M, Kulisevsky J, Weintraub D. Cognitive impairment in nondemented Parkinson's disease. Mov. Disord. 26(14), 2483-2495 (2011).
9. Vossius C, Larsen JP, Janvin C, Aarsland D. The economic impact of cognitive impairment in Parkinson's disease. Mov. Disord. 26(8), 1541-1544 (2011).
10. Aarsland D, Bronnick K, Williams-Gray C et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75(12), 1062-1069 (2010).
11. Litvan I, Goldman JG, Tröster AI et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27(3), 349-356 (2012).
12. Perez F, Helmer C, Foubert-Samier A et al. Risk of dementia in an elderly population of Parkinson's disease patients: a 15-year population-based study. Alzheimers Dement. 8(6), 463-469 (2012).
13. Riedel O, Klotsche J, Spottke A et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J. Neurol. 257(7), 1073-1082 (2010).
14. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23(6), 837-844 (2008).
15. Perez F, Helmer C, Foubert-Samier A, Auriacombe S, Dartigues JF, Tison F. Risk of dementia in an elderly population of Parkinson's disease patients: a 15-year population-based study. Alzheimers. Dement. 8(6):463-9 (2012).
16. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov. Disord. 20(10), 1255-1263 (2005). (Pubitemid 41645899)
17. Poletti M, Frosini D, Pagni C et al. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drugnaive patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 83(6), 601-606 (2012).
18. Aarsland D, Brønnick K, Larsen JP, Tysnes OB, Alves G; Norwegian ParkWest Study Group. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 72(13), 1121-1126 (2009).
19. Aarsland D, Andersen K, Larsen JP et al. The rate of cognitive decline in Parkinson disease. Arch. Neurol. 61(12), 1906-1911 (2004). (Pubitemid 39612951)
20. Williams-Gray CH, Evans JR, Goris A et al. The distinct cognitive syndromes of Parkinson's disease: 5-year follow-up of the CamPaIGN cohort. Brain 132(Pt 11), 2958-2969 (2009).
21. Green J, McDonald WM, Vitek JL et al. Cognitive impairments in advanced PD without dementia. Neurology 59(9), 1320-1324 (2002). (Pubitemid 35285980)
22. Lee AH, Weintraub D. Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. Mov. Disord. 27(7), 858-863 (2012).
23. Aarsland D, Brønnick K, Ehrt U et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J. Neurol. Neurosurg. Psychiatr. 78(1), 36-42 (2007). (Pubitemid 46048261)
24. Verbaan D, van Rooden SM, Visser M, Marinus J, Emre M, van Hilten JJ. Psychotic and compulsive symptoms in Parkinson's disease. Mov. Disord. 24(5), 738-744 (2009).
25. de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch. Neurol. 62(8), 1265-1269 (2005). (Pubitemid 41168354)
26. Williams-Gray CH, Goris A, Saiki M et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J. Neurol. 256(3), 493-498 (2009).
27. Camicioli R, Rajput A, Rajput M et al. Apolipoprotein E epsilon4 and catechol-Omethyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations. Mov. Disord. 20(8), 989-994 (2005). (Pubitemid 41419515)
28. Kurz MW, Dekomien G, Nilsen OB, Larsen JP, Aarsland D, Alves G. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. J. Geriatr. Psychiatry Neurol. 22(3), 166-170 (2009).
29. Ballard CG, Aarsland D, McKeith I et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 59(11), 1714-1720 (2002). (Pubitemid 35424452)
30. Goetz CG, Emre M, Dubois B. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann. Neurol. 64(Suppl. 2), S81-S92 (2008).
31. Meireles J, Massano J. Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. Front. Neurol. 3, 88 (2012).
32. Cognitive Impairment and Dementia in Parkinson's Disease. Emre M (Ed.). Oxford University Press, Oxford, UK (2010).
33. Emre M, Aarsland D, Brown R et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord. 22(12), 1689-707; quiz 1837 (2007). (Pubitemid 47597592)
34. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain 129(Pt 3), 729-735 (2006). (Pubitemid 43278234)
35. Reid WG, Hely MA, Morris JG, Loy C, Halliday GM. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). J. Neurol. Neurosurg. Psychiatr. 82(9), 1033-1037 (2011).
36. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, García- Sánchez C, Gironell A; Trapecio Group Study. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov. Disord. 23(13), 1889-1896 (2008).
37. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov. Disord. 24(15), 2175-2186 (2009).
38. Casanova MF, Starkstein SE, Jellinger KA. Clinicopathological correlates of behavioral and psychological symptoms of dementia. Acta Neuropathol. 122(2), 117-135 (2011).
39. Psychiatry of Parkinson's Disease. Ebmeier KP, O'Brien JT, Taylor J-P (Eds). S. Karger, Basel, Switzerland (2012).
40. Morgante L, Colosimo C, Antonini A et al.; PRIAMO Study Group. Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. J. Neurol. Neurosurg. Psychiatr. 83(1), 76-82 (2012).
41. Gagnon JF, Bertrand JA, Génier Marchand D. Cognition in rapid eye movement sleep behavior disorder. Front. Neurol. 3, 82 (2012).
42. Kotagal V, Albin RL, Müller ML et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann. Neurol. 71(4), 560-568 (2012).
43. Magen I, Chesselet M-F. Mouse models of cognitive deficits due to α-synuclein pathology. J. Parkinson's Dis. 1, 217-227 (2011).
44. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition) Text Revision. American Psychiatric Association, Washington DC, USA (2000).
45. Dubois B, Burn D, Goetz C et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov. Disord. 22(16), 2314-2324 (2007). (Pubitemid 351155975)
46. Dujardin K, Dubois B, Tison F et al.; EXECUTIVE study group. Parkinson's disease dementia can be easily detected in routine clinical practice. Mov. Disord. 25(16), 2769-2776 (2010).
47. Barton B, Grabli D, Bernard B et al. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov. Disord. 27(2), 248-253 (2012).
48. Martinez-Martin P, Falup-Pecurariu C, Rodriguez-Blazquez C et al. Dementia associated with Parkinson's disease: applying the Movement Disorder Society Task Force criteria. Parkinsonism Relat. Disord. 17(8), 621-624 (2011).
49. Docherty MJ, Burn DJ. Parkinson's disease dementia. Curr. Neurol. Neurosci. Rep. 10(4), 292-298 (2010).
50. Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology 75(14), 1270-1276 (2010).
51. Willis AW, Schootman M, Kung N, Evanoff BA, Perlmutter JS, Racette BA. Predictors of survival in patients with Parkinson disease. Arch. Neurol. 69(5), 601-607 (2012).
52. Caviness JN, Driver-Dunckley E, Connor DJ et al. Defining mild cognitive impairment in Parkinson's disease. Mov. Disord. 22(9), 1272-1277 (2007). (Pubitemid 47325034)
53. Petersen RC, Roberts RO, Knopman DS et al. Mild cognitive impairment: ten years later. Arch. Neurol. 66(12), 1447-1455 (2009).
54. Loewenstein DA, Greig MT, Schinka JA et al. An investigation of PreMCI: subtypes and longitudinal outcomes. Alzheimers. Dement. 8(3), 172-179 (2012).
55. Sollinger AB, Goldstein FC, Lah JJ, Levey AI, Factor SA. Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics. Parkinsonism Relat. Disord. 16(3), 177-180 (2010).
56. Tröster AI. A precis of recent advances in the neuropsychology of mild cognitive impairment(s) in Parkinson's disease and a proposal of preliminary research criteria. J. Int. Neuropsychol. Soc. 8, 1-14 (2011).
57. Goldman JG, Weis H, Stebbins G, Bernard B, Goetz CG. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov. Disord. 27(9), 1129-1136 (2012).
58. Dalrymple-Alford JC, Livingston L, MacAskill MR et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov. Disord. 26(4), 629-636 (2011).
59. Goldman JG, Litvan I. Mild cognitive impairment in Parkinson's disease. Minerva Med. 102(6), 441-459 (2011).
60. Liepelt-Scarfone I, Graeber S, Feseker A et al. Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson's disease. Parkinsons. Dis. 2011, 540843 (2011).
61. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov. Disord. 21(9), 1343-1349 (2006). (Pubitemid 44613283)
62. Mitchell AJ, Shiri-Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J. Neurol. Neurosurg. Psychiatr. 79(12), 1386-1391 (2008).
63. Han JW, Lee SB, Kim TH et al. Functional impairment in the diagnosis of mild cognitive impairment. Alzheimer Dis. Assoc. Disord. 25(3), 225-229 (2011).
64. Martínez-Horta S, Kulisevsky J. Is all cognitive impairment in Parkinson's disease "mild cognitive impairment"? J. Neural Transm. 118(8), 1185-1190 (2011).
65. Gasser T, Hardy J, Mizuno Y. Milestones in PD genetics. Mov. Disord. 26(6), 1042-1048 (2011).
66. Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson's disease. Annu. Rev. Genomics Hum. Genet. 12, 301-325 (2011).
67. Jellinger KA. The role of α-synuclein in neurodegeneration-an update. Translat. Neurosci. 3, 75-122 (2012).
68. Fujioka S, Wszolek ZK. Update on genetics of parkinsonism. Neurodegener. Dis. 10(1-4), 257-260 (2012).
69. Saiki S, Sato S, Hattori N. Molecular pathogenesis of Parkinson's disease: update. J. Neurol. Neurosurg. Psychiatr. 83(4), 430-436 (2012).
70. Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol. 6, 193-222 (2011).
71. Poulopoulos M, Cortes E, Vonsattel JP et al. Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J. Mol. Neurosci. 47(1), 139-143 (2012).
72. Kasten M, Kertelge L, Brüggemann N et al. Nonmotor symptoms in genetic Parkinson disease. Arch. Neurol. 67(6), 670-676 (2010).
73. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol. 124(3), 325-338 (2012).
74. Zarranz JJ, Alegre J, Gómez-Esteban JC et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55(2), 164-173 (2004). (Pubitemid 38166992)
75. Stamper C, Siegel A, Liang WS et al. Neuronal gene expression correlates of Parkinson's disease with dementia. Mov. Disord. 23(11), 1588-1595 (2008).
76. Cullen V, Sardi SP, Ng J et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann. Neurol. 69(6), 940-953 (2011).
77. Almeida MR. Glucocerebrosidase involvement in Parkinson disease and other synucleinopathies. Front. Neurol. 3, 65 (2012).
78. Meeus B, Verstraeten A, Crosiers D et al. DLB and PDD: a role for mutations in dementia and Parkinson disease genes? Neurobiol. Aging 33(3), 629.e5-629.e18 (2012).
79. Brockmann K, Srulijes K, Hauser AK et al. GBA-associated PD presents with nonmotor characteristics. Neurology 77(3), 276-280 (2011).
80. Setó-Salvia N, Pagonabarraga J, Houlden H et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Mov. Disord. 27(3), 393-399 (2012).
81. Setó-Salvia N, Clarimón J, Pagonabarraga J et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch. Neurol. 68(3), 359-364 (2011).
82. Morley JF, Xie SX, Hurtig HI et al. Genetic influences on cognitive decline in Parkinson's disease. Mov. Disord. 27(4), 512-518 (2012).
83. Martin WR, Wieler M, Gee M, Camicioli R. Temporal lobe changes in early, untreated Parkinson's disease. Mov. Disord. 24(13), 1949-1954 (2009).
84. Rodriguez MJ, Potter E, Shen Q et al. Cognitive and structural magnetic resonance imaging features of Lewy body dementia and Alzheimer's disease. Alzheimers. Dement. 8(3), 211-218 (2012).
85. Weintraub D, Doshi J, Koka D et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch. Neurol. 68(12), 1562-1568 (2011).
86. Hong JY, Lee JE, Sohn YH, Lee PH. Neurocognitive and atrophic patterns in Parkinson's disease based on subjective memory complaints. J. Neurol. 259(8), 1706-1712 (2012).
87. Weintraub D, Dietz N, Duda JE et al. Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain 135(Pt 1), 170-180 (2012).
88. Camicioli R, Sabino J, Gee M et al. Ventricular dilatation and brain atrophy in patients with Parkinson's disease with incipient dementia. Mov. Disord. 26(8), 1443-1450 (2011).
89. Apostolova L, Alves G, Hwang KS et al. Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment. Neurobiol. Aging 33(9), 2113-2124 (2012).
90. Lee JE, Park B, Song SK, Sohn YH, Park HJ, Lee PH. A comparison of gray and white matter density in patients with Parkinson's disease dementia and dementia with Lewy bodies using voxel-based morphometry. Mov. Disord. 25(1), 28-34 (2010).
91. Melzer TR, Watts R, MacAskill MR et al. Grey matter atrophy in cognitively impaired Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 83(2), 188-194 (2012).
92. Beyer MK, Larsen JP, Aarsland D. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 69(8), 747-754 (2007). (Pubitemid 47300931)
93. Burton EJ, Mukaetova-Ladinska EB, Perry RH, Jaros E, Barber R, O'Brien JT. Neuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia. Neurobiol. Aging 33(7), 1228-1236 (2012).
94. Sanchez-Castaneda C, Rene R, Ramirez-Ruiz B et al. Correlations between gray matter reductions and cognitive deficits in dementia with Lewy Bodies and Parkinson's disease with dementia. Mov. Disord. 24(12), 1740-1746 (2009).
95. Hattori T, Orimo S, Aoki S et al. Cognitive status correlates with white matter alteration in Parkinson's disease. Hum. Brain Mapp. 33(3), 727-739 (2012).
96. Choi SA, Evidente VG, Caviness JN et al. Are there differences in cerebral white matter lesion burdens between Parkinson's disease patients with or without dementia? Acta Neuropathol. 119(1), 147-149 (2010).
97. Bohnen NI, Albin RL. White matter lesions in Parkinson disease. Nat. Rev. Neurol. 7(4), 229-236 (2011).
98. Carlesimo GA, Piras F, Assogna F, Pontieri FE, Caltagirone C, Spalletta G. Hippocampal abnormalities and memory deficits in Parkinson disease: a multimodal imaging study. Neurology 78(24), 1939-1945 (2012).
99. Bohnen NI, Koeppe RA, Minoshima S et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J. Nucl. Med. 52(6), 848-855 (2011).
100. Hosokai Y, Nishio Y, Hirayama K et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov. Disord. 24(6), 854-862 (2009).
101. Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS. Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment. Eur. Neurol. 64(2), 65-73 (2010).
102. Silbert LC, Kaye J. Neuroimaging and cognition in Parkinson's disease dementia. Brain Pathol. 20(3), 646-653 (2010).
103. Ekman U, Eriksson J, Forsgren L, Mo SJ, Riklund K, Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol. 11(8), 679-687 (2012).
104. Nobili F, De Carli F, Frisoni GB et al. SPECT predictors of cognitive decline and Alzheimer's disease in mild cognitive impairment. J. Alzheimers Dis. 17(4), 761-772 (2009).
105. Kantarci K, Lowe VJ, Boeve BF et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol. Aging 33(9), 2091-2105 (2012).
106. Kasanuki K, Iseki E, Fujishiro H et al. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies. J. Neurol. Sci. 314(1-2), 111-119 (2012).
107. Kenny ER, Blamire AM, Firbank MJ, O'Brien JT. Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer's disease. Brain 135(Pt 2), 569-581 (2012).
108. Seibert TM, Murphy EA, Kaestner EJ, Brewer JB. Interregional correlations in Parkinson disease and Parkinson-related dementia with resting functional MR imaging. Radiology 263(1), 226-234 (2012).
109. Galvin JE, Price JL, Yan Z, Morris JC, Sheline YI. Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease. Neurology 76(21), 1797-1803 (2011).
110. Hirano S, Shinotoh H, Eidelberg D. Functional brain imaging of cognitive dysfunction in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 83(10), 963-969 (2012).
111. Walker Z, Jaros E, Walker RW et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J. Neurol. Neurosurg. Psychiatr. 78(11), 1176-1181 (2007). (Pubitemid 350057277)
112. Wolk DA, Price JC, Saxton JA et al. Amyloid imaging in mild cognitive impairment subtypes. Ann. Neurol. 65(5), 557-568 (2009).
113. Gomperts SN, Locascio JJ, Marquie M et al. Brain amyloid and cognition in Lewy body diseases. Mov. Disord. 27(8), 965-973 (2012).
114. Landau SM, Harvey D, Madison CM et al.; Alzheimer's Disease Neuroimaging Initiative. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75(3), 230-238 (2010).
115. Montine TJ, Shi M, Quinn JF et al. CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 25(15), 2682-2685 (2010).
116. Siderowf A, Xie SX, Hurtig H et al. CSF amyloid {β} 1-42 predicts cognitive decline in Parkinson disease. Neurology 75(12), 1055-1061 (2010).
117. Wallin A, Göthlin M, Gustavsson M et al. Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations. Dement. Geriatr. Cogn. Disord. 32(3), 193-197 (2011).
118. Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213(2), 315-325 (2008).
119. Mollenhauer B, Trautmann E, Otte B et al. α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J. Neural Transm. 119(7), 739-746 (2012).
120. Kasuga K, Ikeuchi T. [Cerebrospinal fluid and plasma biomarkers for dementia with Lewy bodies]. Brain Nerve 64(5), 505-513 (2012).
121. Parnetti L, Chiasserini D, Bellomo G et al. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 26(8), 1428-1435 (2011).
122. Reesink FE, Lemstra AW, van Dijk KD et al. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J. Alzheimers Dis. 22(1), 87-95 (2010).
123. Engelborghs S, De Vreese K, Van de Casteele T et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol. Aging 29(8), 1143-1159 (2008). (Pubitemid 351822410)
124. Kasuga K, Tokutake T, Ishikawa A et al. Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatr. 81(6), 608-610 (2010).
125. Compta Y, Martí MJ, Ibarretxe-Bilbao N et al. Cerebrospinal tau, phospho-tau, and β-amyloid and neuropsychological functions in Parkinson's disease. Mov. Disord. 24(15), 2203-2210 (2009).
126. Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat. Disord. 17(1), 61-64 (2011).
127. Parnetti L, Tiraboschi P, Lanari A et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol. Psychiatry 64(10), 850-855 (2008).
128. Bibl M, Esselmann H, Lewczuk P et al. Combined analysis of CSF tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's disease, dementia with Lewy bodies and Parkinson's Disease dementia. Int. J. Alzheimers. Dis. 2010 (2010).
129. Mulugeta E, Londos E, Hansson O et al. Cerebrospinal fluid levels of sAPPa and sAPPβ in Lewy body and Alzheimer's disease: clinical and neurochemical correlates. Int. J. Alzheimers. Dis. 2011, 495025. (2011).
130. Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease. J. Alzheimers Dis. 27(2), 377-384 (2011).
131. Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem. Int. 55(4), 214-218 (2009).
132. Johansen KK, White LR, Sando SB, Aasly JO. Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism Relat. Disord. 16(5), 307-315 (2010).
133. Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia. Int. J. Geriatr. Psychiatry 26(1), 100-105 (2011).
134. Buongiorno M, Compta Y, Martí MJ. Amyloid-β and t biomarkers in Parkinson's disease-dementia. J. Neurol. Sci. 310(1-2), 25-30 (2011).
135. Lehnert S, Jesse S, Rist W et al. iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp. Neurol. 234(2), 499-505 (2012).
136. Stefani A, Brusa L, Olivola E, Pierantozzi M, Martorana A. CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD. J. Neural Transm. 119(7), 861-875 (2012).
137. Warr L, Walker Z. Identification of biomarkers in Lewy-body disorders. Q. J. Nucl. Med. Mol. Imaging 56(1), 39-54 (2012).
138. Jellinger KA. Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. In: Dementia in Clinical Practice. Front Neurol Neurosci, Vol 24. Giannakopoulos P, Hof PR (Eds). Karger, Basel, Switzerland, 114-125 (2009).
139. Kalaitzakis ME, Pearce RK. The morbid anatomy of dementia in Parkinson's disease. Acta Neuropathol. 118(5), 587-598 (2009).
140. Sonnen JA, Postupna N, Larson EB et al. Pathologic correlates of dementia in individuals with Lewy body disease. Brain Pathol. 20(3), 654-659 (2010).
141. Beach TG, Adler CH, Lue L et al.; Arizona Parkinson's Disease Consortium. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117(6), 613-634 (2009).
142. Evans JR, Revesz T, Barker RA. Lesions associated with cognitive impairment and dementia. In: Non-Dopamine Lesions in Parkinson's Disease. Halliday G, Barker RA, Rowe DB (Eds). Oxford University Press, Oxford, UK, 261-287 (2011).
143. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 59(1), 102-112 (2002). (Pubitemid 34052562)
144. Irwin DJ, White MT, Toledo JB et al. Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 72(4), 587-598 (2012).
145. Mattila PM, Rinne JO, Helenius H, Röyttä M. Neuritic degeneration in the hippocampus and amygdala in Parkinson's disease in relation to Alzheimer pathology. Acta Neuropathol. 98(2), 157-164 (1999). (Pubitemid 29355548)
146. Joelving FC, Billeskov R, Christensen JR, West M, Pakkenberg B. Hippocampal neuron and glial cell numbers in Parkinson's disease-a stereological study. Hippocampus 16(10), 826-833 (2006). (Pubitemid 44650900)
147. Irwin DJ, White MT, Toledo JB et al Neuropathologic substrates of Parkinson's disease dementia. Ann. Neurol. 72(4), 587-598 (2012).
148. Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA. Prevalence of amyloid-β deposition in the cerebral cortex in Parkinson's disease. Mov. Disord. 18(1), 81-86 (2003). (Pubitemid 36150209)
149. Oinas M, Polvikoski T, Sulkava R et al. Neuropathologic findings of dementia with Lewy bodies (DLB) in a population-based Vantaa 85+ study. J. Alzheimers Dis. 18(3), 677-689 (2009).
150. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. Brain 132(Pt 11), 2947-2957 (2009).
151. Sabbagh MN, Adler CH, Lahti TJ et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis. Assoc. Disord. 23(3), 295-297 (2009).
152. Braak H, Rüb U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64(8), 1404-1410 (2005). (Pubitemid 40570509)
153. Compta Y, Parkkinen L, O'Sullivan SS et al. Lewy-and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 134(Pt 5), 1493-1505 (2011).
154. Libow LS, Frisina PG, Haroutunian V, Perl DP, Purohit DP. Parkinson's disease dementia: a diminished role for the Lewy body. Parkinsonism Relat. Disord. 15(8), 572-575 (2009).
155. Jellinger KA. Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J. Neural Transm. Suppl. 72, 91-104 (2007).
156. Jellinger KA. Lewy body disorders. In: Degenerative Diseases of the Nervous System. Youdim MBH, Riederer P, Mandel SA, Battistin L, Lajtha A (Eds). Springer Science, New York, NY, USA, 270-343 (2007).
157. Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 115(4), 427-436 (2008).
158. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsyconfirmed Parkinson disease with dementia. Neurology 74(1), 77-84 (2010).
159. Schneider JA, Arvanitakis Z, Yu L et al. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 135(10), 3005-3014 (2012).
160. Foster ER, Campbell MC, Burack MA et al. Amyloid imaging of Lewy bodyassociated disorders. Mov. Disord. 25(15), 2516-2523 (2010).
161. Kotzbauer PT, Cairns NJ, Campbell MC et al. Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch. Neurol. 69(10), 1326-1331 (2012).
162. Dugger BN, Serrano GE, Sue LI et al.; the Arizona Parkinson's Disease Consortium. Presence of striatal amyloid plaques in Parkinson's disease dementia predicts concomitant Alzheimer's disease: usefulness for amyloid imaging. J. Parkinsons. Dis. 2(1), 57-65 (2012).
163. Schwartz RS, Halliday GM, Cordato DJ, Kril JJ. Small-vessel disease in patients with Parkinson's disease: a clinicopathological study. Mov. Disord. 27(12), 1506-1512 (2012).
164. Ghebremedhin E, Rosenberger A, Rüb U et al. Inverse relationship between cerebrovascular lesions and severity of Lewy body pathology in patients with Lewy body diseases. J. Neuropathol. Exp. Neurol. 69(5), 442-448 (2010).
165. van den Berge SA, Kevenaar JT, Sluijs JA, Hol EM. Dementia in Parkinson's disease correlates with α-synuclein pathology but not with cortical astrogliosis. Parkinsons Dis. 2012, 420957 (2012).
166. McKeith IG, Dickson DW, Lowe J et al.; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12), 1863-1872 (2005). (Pubitemid 43970103)
167. Aarsland D, Londos E, Ballard C. Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity. Int. Psychogeriatr. 21(2), 216-219 (2009).
168. Jellinger KA. Interaction between pathogenic proteins in neurodegenerative disorders. J. Cell. Mol. Med. 16(6), 1166-1183 (2012).
169. Kraybill ML, Larson EB, Tsuang DW et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 64(12), 2069-2073 (2005). (Pubitemid 40880995)
170. Deramecourt V, Bombois S, Maurage CA et al. Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J. Neuropathol. Exp. Neurol. 65(3), 278-288 (2006).
171. Alafuzoff I, Ince PG, Arzberger T et al. Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol. 117(6), 635-652 (2009).
172. Fujishiro H, Ferman TJ, Boeve BF et al. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J. Neuropathol. Exp. Neurol. 67(7), 649-656 (2008).
173. Ince PG. Dementia with Lewy bodies and Parkinson's disease dementia. In: Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders (2nd Edition). Dickson DW, Weller RO (Eds). Blackwell Publishing Ltd., Oxford, UK, 224-237 (2011).
174. Masliah E. Recent advances in the understanding of the role of synaptic proteins in Alzheimer's disease and other neurodegenerative disorders. J. Alzheimers Dis. 3(1), 121-129 (2001). (Pubitemid 32238259)
175. Ubhi K, Peng K, Lessig S et al. Neuropathology of dementia with Lewy
176. Halliday GM, Song YJ, Harding AJ. Striatal β-amyloid in dementia with Lewy bodies but not Parkinson's disease. J. Neural Transm. 118(5), 713-719 (2011).
177. Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol. 112(3), 253-260 (2006). (Pubitemid 44275880)
178. Kalaitzakis ME, Walls AJ, Pearce RK, Gentleman SM. Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes. Neurobiol. Dis. 41(2), 377-384 (2011).
179. Fujishiro H, Iseki E, Higashi S et al. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci. Lett. 486(1), 19-23 (2010).
180. Tsuboi Y, Uchikado H, Dickson DW. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat. Disord. 13(Suppl. 3), S221-S224 (2007). (Pubitemid 351215244)
181. Ballard C, Ziabreva I, Perry R et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67(11), 1931-1934 (2006). (Pubitemid 44967366)
182. Aarsland D, Perry R, Larsen JP et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J. Clin. Psychiatry 66(5), 633-637 (2005). (Pubitemid 40733707)
183. Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov. Disord. 22(Suppl. 17), S351-S357 (2007). (Pubitemid 350134188)
184. Sharp SI, Ballard CG, Ziabreva I et al. Cortical serotonin 1 A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia. Dement. Geriatr. Cogn. Disord. 26(4), 330-338 (2008).
185. Jellinger KA. Mild cognitive impairment in Parkinson disease: heterogenous mechanisms. J. Neural Transm. (2012) (Epub ahead of print).
186. Adler CH, Beach TG. Variability of diffuse plaques and amyloid angiopathy in Parkinson's disease with mild cognitive impairment. Acta Neuropathol. 120, 831-832 (2010).
187. Jellinger KA. Neuropathology in Parkinson's disease with mild cognitive impairment. Acta Neuropathol. 120(6), 829-30; author reply 831 (2010).
188. Molano J, Boeve B, Ferman T et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain 133(Pt 2), 540-556 (2010).
189. Markesbery WR. Neuropathologic alterations in mild cognitive impairment: a review. J. Alzheimers Dis. 19(1), 221-228 (2010).
190. Jicha GA, Parisi JE, Dickson DW et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch. Neurol. 63(5), 674-681 (2006).
191. Mufson EJ, Binder L, Counts SE et al. Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol. 123(1), 13-30 (2012).
192. Fujita M, Ichise M, Zoghbi SS et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann. Neurol. 59(1), 174-177 (2006). (Pubitemid 43042884)
193. Albin RL, Dauer WT. Parkinson syndrome. Heterogeneity of etiology; heterogeneity of pathogenesis? Neurology 79(3), 202-203 (2012).
194. Shimada H, Hirano S, Shinotoh H et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73(4), 273-278 (2009).
195. Francis PT. Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD. J. Neurol. 256(Suppl. 3), 280-285 (2009).
196. Shiozaki K, Iseki E, Uchiyama H et al. Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer's disease. J. Neurol. Neurosurg. Psychiatr. 67(2), 209-213 (1999). (Pubitemid 29326955)
197. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 70(16 Pt 2), 1470-1477 (2008). (Pubitemid 351521942)
198. McMillan PJ, White SS, Franklin A et al. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Res. 1373, 240-252 (2011).
199. Hyman BT, Phelps CH, Beach TG et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers. Dement. 8(1), 1-13 (2012).
200. Montine TJ, Phelps CH, Beach TG et al.; National Institute on Aging; Alzheimer's Association. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 123(1), 1-11 (2012).
201. Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann. Neurol. 72(1), 41-52 (2012).
202. van Laar T, De Deyn PP, Aarsland D, Barone P, Galvin JE. Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data. CNS Neurosci. Ther. 17(5), 428-441 (2011).
203. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351(24), 2509-2518 (2004). (Pubitemid 39603164)
204. Chitnis S, Rao J. Rivastigmine in Parkinson's disease dementia. Expert Opin. Drug Metab. Toxicol. 5(8), 941-955 (2009).
205. Weintraub D, Somogyi M, Meng X. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAScog factor analysis. Am. J. Alzheimers. Dis. Other Demen. 26(6), 443-449 (2011).
206. Hiraoka K, Okamura N, Funaki Y et al. Cholinergic deficit and response to donepezil therapy in Parkinson's disease with dementia. Eur. Neurol. 68(3), 137-143 (2012).
207. Emre M, Tsolaki M, Bonuccelli U et al.; 11018. Study Investigators. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9(10), 969-977 (2010).
208. Aarsland D, Ballard C, Walker Z et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 8(7), 613-618 (2009).
209. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst. Rev. 3, CD006504 (2012).
210. Larsson V, Engedal K, Aarsland D, Wattmo C, Minthon L, Londos E. Quality-of-life and the effect of memantine in dementia with Lewy bodies and Parkinson's disease dementia. Dement. Geriatr. Cogn. Disord. 32(4), 227-234 (2011).
211. Graff-Radford J, Boeve BF, Pedraza O et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain 135(Pt 8), 2470-2477 (2012).
212. Dobkin RD, Menza M, Allen LA et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am. J. Psychiatry 168(10), 1066-1074 (2011).
213. Dobkin RD, Rubino JT, Allen LA et al. Predictors of treatment response to cognitive-behavioral therapy for depression in Parkinson's disease. J. Consult. Clin. Psychol. 80(4), 694-699 (2012).
214. Menza M, Dobkin RD, Marin H et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72(10), 886-892 (2009).
215. Seppi K, Weintraub D, Coelho M et al. The Movement Disorder Society evidencebased medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 26(Suppl. 3), S42-S80 (2011).
216. Barone P, Poewe W, Albrecht S et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9(6), 573-580 (2010).
217. Drijgers RL, Verhey FR, Tissingh G, van Domburg PH, Aalten P, Leentjens AF. The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate. J. Neurol. Sci. 320(1-2), 121-126 (2012).
218. McDermott CL, Gray SL. Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression. Ann. Pharmacother. 46(4), 599-605 (2012).
219. Drach LM. [Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia-common features and differences]. Med. Monatsschr. Pharm. 34(2), 47-52; quiz 53 (2011).
220. Aarsland D, Ballard C, Rongve A, Broadstock M, Svenningsson P. Clinical trials of dementia with lewy bodies and Parkinson's disease dementia. Curr. Neurol. Neurosci. Rep. 12(5), 492-501 (2012).
221. Jankovic J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatr. 79(4), 368-376 (2008). (Pubitemid 351441488)